149 related articles for article (PubMed ID: 20182366)
21. Topical recombinant human thrombin in surgical hemostasis.
Bowman LJ; Anderson CD; Chapman WC
Semin Thromb Hemost; 2010 Jul; 36(5):477-84. PubMed ID: 20632245
[TBL] [Abstract][Full Text] [Related]
22. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin.
Israels SJ; Israels ED
Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):249-54. PubMed ID: 8037345
[TBL] [Abstract][Full Text] [Related]
23. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
Adams JD; Jones S; Brost BC
J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
[TBL] [Abstract][Full Text] [Related]
24. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
25. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis.
Chapman WC; Singla N; Genyk Y; McNeil JW; Renkens KL; Reynolds TC; Murphy A; Weaver FA
J Am Coll Surg; 2007 Aug; 205(2):256-65. PubMed ID: 17660072
[TBL] [Abstract][Full Text] [Related]
26. Antihuman factor V antibodies after use of relatively pure bovine thrombin.
Lawson JH; Lynn KA; Vanmatre RM; Domzalski T; Klemp KF; Ortel TL; Niklason LE; Parker W
Ann Thorac Surg; 2005 Mar; 79(3):1037-8. PubMed ID: 15734434
[TBL] [Abstract][Full Text] [Related]
27. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery.
Flaherty MJ; Henderson R; Wener MH
Ann Intern Med; 1989 Oct; 111(8):631-4. PubMed ID: 2802417
[TBL] [Abstract][Full Text] [Related]
28. Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis.
Paterson CA; Pixton GC; Proskin HM; Massaro JM; Morasch M; Cronstein B; Fareed J; Ofosu FA
Clin Appl Thromb Hemost; 2011; 17(6):620-32. PubMed ID: 21596694
[TBL] [Abstract][Full Text] [Related]
29. Perioperative topical bovine thrombin exposure is not associated with hemodialysis graft thrombosis.
Vannorsdall MD; Arkel YS; Ku DH; Lucas FL; Himmelfarb J
Kidney Int; 2003 Aug; 64(2):690-6. PubMed ID: 12846767
[TBL] [Abstract][Full Text] [Related]
30. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery.
Doria C; Fischer CP; Wood CG; Li PM; Marra S; Hart J
Curr Med Res Opin; 2008 Mar; 24(3):785-94. PubMed ID: 18241525
[TBL] [Abstract][Full Text] [Related]
31. Topical use of recombinant human thrombin for operative hemostasis.
Anderson CD; Bowman LJ; Chapman WC
Expert Opin Biol Ther; 2009 Jan; 9(1):133-7. PubMed ID: 19063699
[TBL] [Abstract][Full Text] [Related]
32. Bovine thrombin: history, use, and risk in the surgical patient.
Diesen DL; Lawson JH
Vascular; 2008; 16 Suppl 1():S29-36. PubMed ID: 18544303
[TBL] [Abstract][Full Text] [Related]
33. Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations.
Voils SA
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):18S-22S. PubMed ID: 19558281
[TBL] [Abstract][Full Text] [Related]
34. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis.
Singla NK; Ballard JL; Moneta G; Randleman CD; Renkens KL; Alexander WA
J Am Coll Surg; 2009 Jul; 209(1):68-74. PubMed ID: 19651065
[TBL] [Abstract][Full Text] [Related]
35. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin.
Zehnder JL; Leung LL
Blood; 1990 Nov; 76(10):2011-6. PubMed ID: 2242423
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human thrombin: safety and immunogenicity in pediatric burn wound excision.
Foster KN; Mullins RF; Greenhalgh DG; Gamelli RL; Glat P; Lentz CW; Kahn SA; Brandigi C; Fredlund P; Alexander WA
J Pediatr Surg; 2011 Oct; 46(10):1992-9. PubMed ID: 22008340
[TBL] [Abstract][Full Text] [Related]
37. The clinical use and immunologic impact of thrombin in surgery.
Lawson JH
Semin Thromb Hemost; 2006 Apr; 32 Suppl 1():98-110. PubMed ID: 16673271
[TBL] [Abstract][Full Text] [Related]
38. Topical thrombins: benefits and risks.
Lomax C; Traub O
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):8S-12S. PubMed ID: 19558279
[TBL] [Abstract][Full Text] [Related]
39. Management of wounds treated by thrombin coagulation.
Higuchi D; Sei Y; Suzuki T; Takiuchi I
Burns Incl Therm Inj; 1987 Feb; 13(1):75-6. PubMed ID: 3548911
[TBL] [Abstract][Full Text] [Related]
40. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin.
Israels SJ; Leaker MT
J Pediatr; 1997 Sep; 131(3):480-3. PubMed ID: 9329435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
